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Abstract
Hepatocellular carcinoma (HCC) is an intrinsically chemotherapy refractorymalignancy. Development of effective thera-
peutic regimens would be facilitated by improved preclinical HCC models. Currently, most models consist of subcuta-
neous human tumor transplants in immunodeficient mice; however, these do not reproduce the extensive liver disease
associated with HCC or metastasize. To address this deficiency, we developed an orthotopic model. Human HCC cells
were transfectedwith the gene encoding secretableβ-subunit humanchoriogonadotropin (β-hCG),whichwasused as a
surrogate marker of tumor burden. The HCC cells were implanted into the left liver lobe of severe combined immuno-
deficient (SCID) mice, after which the efficacy of different therapies was evaluated on established, but liver-confined
human Hep3B cell line HCC. Treatments included sorafenib or metronomic chemotherapy using cyclophosphamide
(CTX), UFT, an oral 5-fluorouracil prodrug, or doxorubicin either alone or in various combinations, with or without an
antiangiogenic agent, DC101, an anti–vascular endothelial growth factor receptor-2 antibody. Sorafenib inhibited tumor
growth in a dose-dependent manner but caused severe weight loss in SCID mice, thus necessitating use of DC101 in
subsequent experiments. Although less toxicitywas observed using either single or doubletmetronomic chemotherapy
without any added antiangiogenic agent, none, provided survival benefit. In contrast, significantly improved overall sur-
vivalwasobservedusingvarious combinationsofmetronomic chemotherapy regimens suchasUFT+CTXwithDC101.
In conclusion, using this model of liver-confined but advanced HCC suggests that the efficacy of a targeted antiangio-
genic drug or metronomic chemotherapy can be mutually enhanced by concurrent combination treatment.
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Introduction
A recurring concern regarding experimental therapeutic studies in
oncology using various types of tumor models in mice is the frequent
discrepancy of the antitumor efficacy results obtained using such mod-
els, which are often impressive, with the much more modest or negative
results obtained in subsequent clinical trials [1–4]. There are a number
of possible factors that can help explain this fundamental gap in trans-
lational research, one of which is the presence, or not, of advanced me-
tastatic disease [1]. Typically, most patients in phase 1, 2, and 3 clinical
trials have advanced disease involving high-volume visceral metastases
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in one or multiple organ sites; often, such patients have received previ-
ous therapies and thus have “refractory” disease. Successful treatment of
such metastatic patients with new therapeutic regimens/drugs is much
more difficult compared with patients with low-volume, asymptomatic
micrometastatic disease or small, surgically resectable solitary tumors,
whether primary or metastatic in nature. Yet, virtually all experimental
therapy preclinical investigations in mice have historically involved
models of localized, encapsulated primary tumors, usually implanted
subcutaneously, as well as spontaneously arising tumors in genetically
engineered mouse models or low-volume microscopic metastases at the
time treatment was initiated [1].
To address this fundamental problem, we have been developing new
models of advanced disease, including visceral metastases, using human
tumor xenografts in immune deficient mice for testing various new
drugs and treatment strategies, especially long-term low-dose metro-
nomic chemotherapy regimens [5–8]. The therapeutic outcomes are
compared with those testing the same therapy using the identical tumor
cell line grown as a primary tumor transplant, either subcutaneously
or orthotopically. The first such model we developed involved breast
cancer using the human MDA-MB-231 cell line [5]; and the second,
metastatic melanoma using theWM-239 cell line [6]. In both cases, the
basic strategy involved serial selection of highly metastatic variant sub-
lines using a multistep procedure of orthotopic primary tumor implanta-
tion, surgical resection of the established primary tumor, and the recovery
of emergent lung metastases months later [5,6,9]. More recently, we
have also generated Her-2/erbB-2–positive highly metastatic variants of
MDA-MB-231, which are “tagged” with markers to allow serial assess-
ment of disease burden and response to therapy, for example, the secreted
β-subunit of human choriogonadotropin hormone (β-hCG) measured
in the urine [8–10] or luciferase, allowing whole-body bioluminescent
imaging of tumor [11].
Using these aforementioned models, we have reported a number of
actual or potentially clinically relevant observations. For example, mono-
therapy with targeted biologic drugs such as trastuzumab failed to induce
a survival effect when used as a monotherapy to treat mice with ad-
vanced established human breast cancer metastases in severe combined
immunodeficient (SCID) mice, whereas the expected growth delay was
caused when used to treat localized primary tumors [9]. We have ob-
served similar results using antiangiogenic drugs such as DC101, the
antibody to vascular endothelial growth factor receptor-2 (VEGFR-2)
[1]. Surprisingly, however, the opposite pattern has been observed when
testing long-term oral “doublet” chemotherapy regimens, for example,
low-dose cyclophosphamide (CTX) and low-dose UFT, a 5-fluorouracil
(5-FU) prodrug, in an advanced human metastatic breast cancer model
[5]. The remarkable antimetastatic effect of the CTX/UFT doublet
combination was pivotal in the decision to initiate a phase 2 trial of daily
low-dose metronomic capecitabine (another oral 5-FU prodrug) and
CTX, combined with bevacizumab, for the treatment of metastatic
breast cancer, the results of which were highly encouraging [12]. In
another model, involving a highly metastatic melanoma variant, we
observed the emergence of spontaneous brain metastases in long-term
surviving mice treated with long-term metronomic vinblastine and
CTX [6], a finding that reflects an increasingly common clinical phe-
nomenon observed when certain types of cancer patients with visceral
metastatic disease attain significant therapy-induced prolongation of
survival [6,13–15].
With these precedents in mind, we decided to develop a new model
of advanced human hepatocellular carcinoma (HCC) in immune defi-
cient mice with which to study the impact of various investigational
metronomic chemotherapy regimens and/or targeted antiangiogenic
drugs such as sorafenib or DC101, the antimouse VEGFR-2 antibody.
The decision to study HCC was based on several considerations. First,
in addition to being one of the most lethal of all malignancies, until
recently, there was no successful systemic therapy available to treat
advanced HCC. However, sorafenib, a multitargeted antiangiogenic
receptor tyrosine kinase inhibitor (RTKI) was recently approved for
advanced HCC based on modest but statistically significant survival ad-
vantages observed in pivotal randomized phase 3 clinical trials [16,17].
In contrast, chemotherapy has marginal, if any, benefit when used at
conventional doses and schedules [18,19]. The use of toxic conven-
tional maximum tolerated dose chemotherapy is also made difficult by
the comorbidity of liver dysfunction that often presents in HCC pa-
tients [20]. However, less toxic low-dose metronomic chemotherapy
regimens might, in some circumstances, constitute an alternative and
feasible form of chemotherapy for both advanced and early stage
HCC, especially when combined with a targeted, biologic antiangio-
genic drug, as shown in other systems [21,22]. To this end, we report
here the details of an advanced orthotopic HCC therapy model we have
developed and its use in long-term therapy investigations involving vari-
ous empiric metronomic chemotherapy regimens when these are com-
bined with a biologic VEGF pathway–targeting antiangiogenic drug.
The model involves orthotopic transplantation of a human HCC cell
line; however, in this case, the tumor(s) that arose in the liver were not
resected, to allow locally advanced progression of the disease within this
organ site. This approach was taken because most advanced HCC pa-
tients die of heavy disease burden confined to the liver without necessarily
having evidence of macroscopic distant metastases. Here, we report
promising results showing significant prolonged overall survival with
minimal associated toxicity using doublet metronomic chemotherapy
combinations such as UFT and CTX with DC101.
Materials and Methods
Cell Lines
The human HCC cell lines PLC and Hep3B were purchased from
ATCC (Manassas, VA). They were maintained in Dulbecco’s modified
Eagle medium (DMEM) with high glucose (Hyclone, UT) supple-
mented with 10% heat-inactivated fetal bovine serum (Hyclone) at
37°C in a humidified atmosphere containing 5% CO2. Hep3B and
PLC cells were transfected with the hCG.pIRES vector and hCG-
expressing variants (Hep3B-hCG and PLC-hCG) were obtained
by puromycin selection. The hCG.pIRES vector carries the gene for
β-hCG, and the secreted protein can be detected in the urine as a
surrogate marker for tumor burden [10]. Clones (Hep3B-hCG and
PLC-hCG) were used for the experiment based on the highest levels
of protein expression. Cells are dissociated by trypsin, washed once
in serum-containing DMEM followed by two washes in serum-free
DMEM. Cells are resuspended in serum-free DMEM for implantation.
Animals
Female CB17 SCID (Charles River Canada, Quebec, Canada) or
athymic nude (nu/nu) mice (Harlan, Indiana) between 6 and 8 weeks
of age were used. All animals were housed in microisolator cages, and
procedures were carried out in accordance with institutional guidelines
for proper animal care and maintenance.
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β-hCG Measurements
Urine β-hCGwasmeasured with the commercially available Pathzyme
Free β-hCG ELISA Kit (Omega Diagnostics Ltd, Scotland, UK), which
allows for quantitative determination of β-hCG. Urine β-hCG levels
were normalized by concomitant measurement of urine creatinine levels
(using QuantiChrom Creatinine Assay Kit; BioAssay Systems, Hayward,
CA) as detailed by Shih et al. [10]. Urine was collected by placing mice
individually into small sterile aerated boxes for 2 hours.
Subcutaneous (Ectopic) Transplantation of Human HCC Cells
A bolus of 5 million Hep3B-hCG cells was injected subcutaneously
into CB-17 SCID mice. Tumor size was assessed weekly by means of
Vernier calipers and the following formula: (w1 ×w2 ×w2) / 2, wherew1
and w2 are the length and width (mm), respectively.
Orthotopic Liver Implantation
Aseptic technique was used throughout the surgical procedure. The
anesthetized mouse was laid on its back, and a 1-cm transverse incision
was made through the skin and peritoneum of the left upper abdomen.
A portion of the liver was exposed by applying gentle pressure on the
abdomen. A bolus of 106 cells in a 10-μl volume was injected into the
subsera of the liver using a Hamilton syringe and 30-gauge needle. After
swabbing the area with sterile gauze, the pressure was removed from
the abdomen allowing the liver to slip back into place. The peritoneum
was closed with 4.0 absorbable sutures, and the skin was closed with
wound clips.
β-hCG Immunostaining of Tumors
Formalin-fixed tumor and tissue sections were deparaffinized and
rehydrated by standard histology protocols. The slides were then placed
in preheated 10 mM citrate buffer (pH 6.0) in a pressure cooker and
incubated for 20 to 40 minutes for antigen retrieval. After washing the
slides in Tris-buffered saline twice for 2 minutes at room temperature,
the slides were then immersed in 3% hydrogen peroxide for 15 minutes
at 22°C to quench endogenous peroxidase activity. The specimens were
preblocked for 30 minutes at room temperature in normal goat serum.
Subsequently, the slides were incubated for 30 minutes with rabbit
anti–β-hCG polyclonal antibody (dilution at 1:300; Dako, Glostrup,
Denmark) at room temperature. After three washes in Tris-buffered
saline, the signal was visualized by using the Zymed LAB-SA detection
system (Zymed Laboratories, Inc, San Francisco, CA). Positive staining
of β-hCG was indicated as reddish brown.
Drugs and Treatment Schedules Used for Therapy
The antiangiogenic drug sorafenib tosylate is an oral multitargeting
RTKI and this was generously provided byBayer (Leverkusen,Germany).
Targets include VEGFR-2 and VEGFR-3 and platelet-derived growth
factor receptors, C-RAF and B-RAF. Sorafenib was prepared fresh daily
just before gavaging and was dissolved in cremophor EL/95% ethanol/
water (12.5:12.5:75) as described previously [23,24]. The drug was
administered by gavage, once daily for 35 days at dose levels of 15, 30,
and 60 mg/kg body weight starting at around day 12 to 14 when all ani-
mals in the study had evidence of established tumors averaging from
100 to 150 mg, which was estimated from the β-hCG analysis to be
12.27 ± 9.24 mIU/ml (Figure 2B), with five mice per group.
For chemotherapy treatments, we used UFT, a 5-FU oral prodrug,
which consists of a 4:1 molar combination of uracil and tegafur in 0.1%
hydroxypropylmethyl cellulose [25,26].
Tegafur, uracil, and the hydroxypropylmethyl cellulose were gener-
ously supplied by Taiho Pharmaceutical Co, Ltd (Tokyo, Japan). UFT
was prepared fresh daily just before gavaging. CTX (Baxter Oncol-
ogy GmbH, Mississauga, Ontario, Canada) and doxorubicin (DOX)
(Novopharm, Toronto, Ontario, Canada) were purchased from the
institutional pharmacy. CTX was reconstituted as per manufacturer’s
instructions to a stock concentration of 20 mg/ml and administered
through drinking water to provide an estimated dose of 20 mg/kg
per day of CTX based on the estimated daily consumption of 3 ml
for a 20-g mouse, as previously described [27]. DOXwas freshly diluted
with saline and administered intraperitoneally (0.6 or 0.5 mg/kg) three
times a week. Another antiangiogenic drug, DC101, the antimouse
VEGFR-2 monoclonal antibody, was used as previously described,
that is, at a dose of 800 μg per mouse, injected intraperitoneally every
3 days [21].
Statistical Analysis
Results are reported as the mean (SD). Statistical significance of
differences in the sorafenib therapy experiments was assessed by two-
way analysis of variance. Survival curves were generated by the Kaplan-
Meier method, and the statistical significance of differences in survival
was assessed by χ 2 test. All statistics was generated by using GraphPad
Prism 4.00 software for windows, GraphPad Software, San Diego, CA
(www.graphpad.com). The level of significance was set at P < .05.
Results
Noninvasive Serial Monitoring of Orthotopic Primary HCC
Growth Using the β-hCG Marker
We first developed a preclinical orthotopic model of human HCC in
SCID mice in which human HCC cells were implanted directly into
the liver (Figure 1A). Monitoring changes in tumor size in this model
using traditional methods such as caliper measurements is obviously
not possible. Clearly, the ability to measure changes in tumor burden
is important for such decisions such as when to initiate therapy if treat-
ment of established liver disease is an objective. We therefore developed
a noninvasive approach to measure and monitor HCC growth, which
involves transplantation of tumor cells that have been transfected with
the gene for β-hCG. The protein is secreted from the cells, detected in
the urine, and can be used, similar in principle to prostate-specific anti-
gen in prostate cancer, as a surrogate molecular marker of relative tumor
burden and response to therapy [9]. To this end, we successfully tagged
two HCC cell lines, PLC and Hep3B, with the gene for β-hCG.
Three mice were implanted with 106 PLC-hCG or Hep3B-hCG
cells. All tumors grew locally in the liver, either as clusters of nodules
(PLC; Figure 1B) or as a solitary nodule (Hep3B; Figure 1C). We chose
Hep3B-hCG for the remainder of the experiments because solitary liver
tumor nodules are much easier to surgically resect. As such, this model
would be useful for future experiments involving surgical resection of
the primary liver tumor followed either immediately by adjuvant ther-
apy, or initiating therapy at later times for established metastatic disease,
the results of which could then be compared with those obtained in
this study. In addition, similar to HCC in humans, the Hep3B-hCG
tumors growing in the liver have an abundant vasculature, more so than
the PLC-hCG cell line (Tang et al., unpublished observations), thus
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making it ideal to investigate antiangiogenic drug treatments. Successful
orthotopic implantation was achieved in 11 of 12 mice without signs
of macroscopic incidence of tumor dissemination because of leakage
of tumor cells from the site of implantation. Two mice died before
the end point of the experiment (7 weeks after HCC implantation) be-
cause of large tumor burdens.
Levels of β-hCG seemed to reflect relative tumor burden/size in
SCID mice during a 6-week period of observation (Figure 2A). One
mouse (#2-1), in which no tumor developed, did not have detectable
β-hCG levels (Figure 2A). As seen in Figure 2A, there was a 2- to
3-week latency period, after which tumor burden increased rapidly.
On the basis of this result, we estimated that an appropriate time for
initiating chemotherapy for established disease in this model would be
between 2 and 3 weeks. In contrast, initiating treatment during the first
week could be viewed as an experimental model of early stage (low-
volume) disease therapy, which would be useful for future adjuvant-like
therapy model experiments.
We also performed subcutaneous implantations of Hep3B-hCG in
four mice to study tumor growth in this conventional treatment model.
We collected urine samples and measured tumor size at the same time
on a weekly basis. The rationale for this experiment was to obtain the
timeline and pattern of tumor growth, which could be compared with
the results in the orthotopic transplant model. One mouse did not
develop a tumor, and again, this was paralleled by undetectable urine
β-hCG levels. For the orthotopic model, the weight and urine samples
to assess β-hCG levels were collected before termination of the experi-
ment. We combined the data from ectopic (subcutaneous) and ortho-
topic models to evaluate the correlation of β-hCG with tumor size. The
results (shown in Figure 2B) indicate a trend of a linear relationship be-
tween tumor size and β-hCG levels, although the correlation did not
reach statistical significance (Figure 2B; regression coefficient, 0.3306;
P < .0646). Thus, in addition to using β-hCG measurements, we in-
cluded survival times in our subsequent experiments to evaluate the
therapeutic impact of the various drugs we tested.
Figure 1. Summary of the development of an orthotopic HCC model. (A) One million human HCC cells expressing β-hCG were implanted
into the left lobe of the liver of SCID mouse, as described in Materials and Methods. (B) At week 6 after PLC-hCG cell implantation,
multiple tumor nodules developed in liver, indicated by the yellow arrows. (C) Hep3B-hCG cells developed into a single tumor mass in
the liver 6 weeks after cell implantation. Normal liver is indicated by blue arrowheads.
Figure 2. Human β-hCG levels in urine samples from HCC-bearing SCID mice. (A) The relative HCC tumor burden is reflected by the level
of β-hCG detected in urine samples (n = 12). Note that the latency period for growth of the HCC tumors is approximately 2 to 3 weeks.
(B) Correlation of tumor mass and urine β-hCG levels from the pooled data obtained from the subcutaneous (n = 4) and orthotopic
transplant models (n = 10).
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Suppressed β-hCG Levels Detected in Response to
Sorafenib Treatment
Systemic therapywith sorafenib demonstrated efficacy in randomized
phase 3 clinical trials of HCC patients [16,17], and it is now approved
for this indication. We therefore decided to test this drug to determine
whether it had efficacy in our preclinical HCC models. To do so, we
implanted the Hep3B-hCG cell line subcutaneously or orthotopically,
allowed the tumors to grow for 2 weeks, then treated the mice with 15,
30, or 60 mg/kg of sorafenib for 30 days. Subcutaneously grown HCC
tumors responded to sorafenib therapy in a dose-dependent manner,
with 60 mg/kg providing the best response (Figure 3A). This was ac-
curately reflected by the detected β-hCG in the urine (Figure 3B), vali-
dating the use of this protein as a surrogate marker of tumor burden
and response to therapy. On the basis of this observation, orthotopically
grown HCC tumors also responded well to sorafenib therapy; whereas
overall β-hCG levels were higher in mice with orthotopic tumors com-
pared with subcutaneous tumors, only the controls showed a large
increase in detectable β-hCG (Figure 3C ). Unfortunately, sorafenib
therapy showed significant toxicity—as evidenced by weight loss—
which was more severe in mice with subcutaneous tumors compared
with orthotopic tumor-bearing mice (Figure 3,D and E ). This toxicity
seems to be related to the use of many different RTKIs in SCID mice
and is not restricted to sorafenib [28] (Tang et al., unpublished observa-
tions). Interestingly, tumor weights of the control group, taken on sac-
rifice at day 44, were significantly greater than those in the orthotopic
model (Figure 3F ) and may be a reflection of the tumor growing more
robustly in its appropriate microenvironment.
Histopathologic Detection of Hepatic Metastatic Foci after
Hepatectomy Shows Stability of β-hCG as a Biomarker
To confirm the stability of β-hCG expression in the transfected HCC
cells in vivo, we resected primaryHCC tumors from the left liver lobes in
two mice 7 weeks after implantation of Hep3B cells; mice were killed
8 weeks after hepatectomy. Immunohistochemical staining of anti–β-
hCG (Figure 4) in paraffin sections showed the typical well-differentiated
HCC cells in liver tissue. β-HCG in recurrent and metastatic HCC
tumors was expressed predominantly in the cytoplasm of tumor cells
(Figure 4, reddish brown).
Figure 3. Dose-response of sorafenib treatment in the HCC orthotopic and ectopic (subcutaneous) tumor therapymodels (n= 5). (A) Tumor
volumes in subcutaneous transplant model; sorafenib induced a dose-dependent inhibition of tumor volumes. (B) Relationship of β-hCG
levels and relative tumor volume in the subcutaneous transplant model shown in Fig. 3A (n = 5). β-HCG levels correlated with tumor
volumes. (C) Relationship of β-hCG levels and relative tumor volumes in HCC transplant models; β-hCG levels parallel relative tumor
volumes in a dose-dependent manner. (D) Relative mouse weights in the subcutaneous HCC transplant model. Toxicity was detected after
7 days treatment with both the 30- and 60-mg/kg per day doses of sorafenib. (E) Relative weights detected in one orthotopic transplant
model; toxicity became apparent after 7 days treatment at the 60 mg/kg/day dose. (F) Comparisons of tumor mass in the orthotopic and
subcutaneous transplant models. The tumor mass in the orthotopic model control group is significantly greater compared with the subcu-
taneous transplant model group (P = .0029). The vertical arrows in panels A to E represent start of sorafenib treatment.
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Therapeutic Impact of Metronomic Chemotherapy with or
without a VEGF Pathway–Targeting Drug
We reported previously that certain low-dose metronomic chemo-
therapy regimens significantly prolonged the overall survival of mice
with advanced metastatic human breast cancer or melanoma, espe-
cially the former [5,6], as well as advanced ovarian cancer [29]. We also
reported, as have others, that the efficacy of metronomic chemotherapy
can be significantly enhanced by combination with an antiangiogenic
drug [21,22,29–31]. We therefore decided to test metronomic chemo-
therapy in combination with an antiangiogenic drug in our model
of advanced HCC. However, because of the toxicity associated with
long-term sorafenib treatment in SCID mice, we decided to test vari-
ous monotherapy or combination metronomic chemotherapy regimens
(using UFT, CTX, and/or DOX) with or without the antiangiogenic
agent DC101, the antimouse anti–VEGFR-2 monoclonal antibody,
which we have used extensively in previous studies involving SCID
mice [21,32]. Various single or combination metronomic chemother-
apy regimens—without DC101—on established tumors (based on
β-hCG levels) did not result in a statistically significant survival benefit
in the Hep3B HCCmodel (Figure 5, A and B). There was also no pro-
longation of survival using CTX ± DC101 in the PLC HCC model
or the Hep3B model (data not shown). However, combining metro-
nomic chemotherapy using UFT and CTX or UFT + DOX with
DC101 produced a statistically significant benefit in overall survival
times (Figure 5B). The statistical significance values of overall sur-
vival in metronomic chemotherapy treatments are listed in Table 1.
The most effective metronomic chemotherapy regimen when com-
bined with DC101 (based on the median survival) was the two-drug
CTX + UFT chemotherapy combination (78.5 days, P = .0067;
Figure 5B and Table 1). As a means of visualizing the results of Figure 5
in a more comprehensive and comparative way (given the large num-
ber of groups), we have provided an expanded version showing indi-
vidual survival curves of each treatment group compared with the
control group.
Discussion
HCC is one of the five most common malignancies in the world with
a particularly high incidence in Asian countries [33–35]. However, the
incidence of the disease in North America has been rising rapidly in
recent years, likely owing to increased cases of hepatitis C and B virus
infection [33–35]. HCC is a highly malignant tumor characterized by
active neovascularization [36].With respect to therapy, surgical resection
is a potentially curative therapy. The current surgical mortality of hepa-
tectomy for HCC is approximately 5% or less in major centers with
surgical expertise and careful patient selection [37]. However, tumor
resection is limited to patients with good liver function (i.e., Child A
cirrhosis with no or only minimal portal hypertension) [37,38]. Al-
though long-term survival after resection of HCC has improved with a
current overall 5-year survival rate of approximately 50% [37,38], there
aremany cases where surgery is not possible owing to the proximity of the
tumor to the hepatic artery. Furthermore, recurrence and metastasis of
HCC are major impediments compromising prolonged survival after
surgical resection.Moreover, there is no effective neoadjuvant or adjuvant
chemotherapy for HCC, thus the need for better systemic therapies is
both obvious and urgent.
Figure 4. Evidence of b-hCG expression in vivo and of metastatic and recurrent HCC after surgical resection of primary tumor mass by
immunohistochemical staining. Hepatectomy was performed in two mice 7 weeks after implantation of Hep3B cells in the liver. Immuno-
histochemical staining was done with anti–β-hCG antibody on formalin-fixed paraffin sections. The liver (A) and lung (B) specimens
were collected 8 weeks after hepatectomy. Reddish brown staining indicates positive β-hCG staining of HCC cells. Red arrows indicate
HCC metastasis.
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Figure 5. Combination of various low-dose metronomic (LDM) chemotherapy regimens/drugs with or without DC101 in the orthotopic
Hep3B HCC model (n = 5 per group). (A) Survival curves observed using single and combination LDM chemotherapy treatments, without
DC101. (B) Survival curves using combination LDM chemotherapy treatments with or without DC101. The smaller lower five graphs shown
in panels A and B are taken from the larger figure at the top of panels A and B. Together, these smaller graphs comprise the larger composite
graph and are shown to more clearly illustrate the differences or similarities between each treatment group and the control untreated group.
Note the prolongation of survival when metronomic UFT + CTX or UFT + DOX is combined with DC101. UFT = tegafur + uracil, a 5-FU
prodrug. See Table 1 for median survival times and statistical significance.
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Developing improved therapies for HCC would be facilitated by the
availability of preclinical rodent models that better reflect the malignant
nature of HCC. Few, if any, such models presently exist. Instead, most
models consist of subcutaneous (ectopic) tumors of human HCC cells
grown in immune deficient mice. This has been a standard methodology
for decades for a number of reasons: the procedure is easy to perform
and is minimally invasive and changes in tumor size are readily moni-
tored by caliper measurements. Unfortunately, such models do not ac-
curately reflect certain aspects of the respective clinical disease because
the tumors are grown and treated in an ectopic and thus possibly in-
appropriate microenvironment. Indeed, previous studies involving com-
parisons between orthotopic and ectopic subcutaneous tumors have
shown differences in invasiveness, angiogenesis, ability to metastasize,
and response to therapy [39,40]. Advanced orthotopic HCC models,
Figure 5. (continued).
Neoplasia Vol. 12, No. 3, 2010 Metronomic Chemotherapy of Locally Advanced HCC Tang et al. 271
possibly in conjunction with distant metastases, would thus represent a
potentially significant improvement for studying both the biology and
treatment of HCC. Although some orthotopic HCC models have been
developed, they have not taken into consideration the serial monitoring
of tumor burden, which is a crucial experimental factor in the timing of
initiation of therapy as well as the detection of recurrent disease or metas-
tases in vivo [41,42]. In the case of HCC, orthotopic models suffer from
the handicap of not being able to accurately monitor tumor size in the
liver. To circumvent this problem, we have transfected the β-hCG gene
into human PLC and Hep3B HCC cell lines, which can be used as an
independent quantitative surrogate marker of tumor burden. The detec-
tion of secreted β-hCG by transfected cell lines has previously been used
by us as a means of noninvasively monitoring tumor growth over long
periods, including metastases [8,9,32]. Indeed, a linear relationship ex-
isted between detected β-hCG and tumor size, although this did not quite
reach statistical significance (Figure 2B). However, it seems that β-hCG
levels accurately reflected relative tumor burden—indicated by increasing
levels of β-hCG, whereas low tumor burden induced by therapy was ac-
companied by barely detectable levels of β-hCG (Figure 3B). Therefore,
β-hCG is a valid surrogate marker of tumor burden and response. Also of
interest is the fact that the expression of β-hCG by theHCC cells allowed
us to use anti–β-hCG antibodies for immunohistochemical staining of
tumor cells in vivo, as shown in Figure 4.
A potential weakness and limitation of our advanced HCC model
from the standpoint of undertaking therapy experiments and their po-
tential clinical relevance is the absence of liver cirrhosis. This is frequently
a comorbid condition observed in HCC patients and is a significant fac-
tor in limiting the use of conventional chemotherapy for the treatment
of HCC [18,19]. HCC are secondary to either a viral hepatitis infection
or cirrhosis, but most cases of HCC are caused by viral hepatitis in-
fection. In fact, the cell lines we used are hepatitis B virus–integrated.
However, with respect to chemotherapy, our major therapeutic interest
is the use of very low nontoxic or minimally toxic doses of chemother-
apy administered in close, regular intervals with no prolonged breaks
(i.e., metronomic chemotherapy), used alone or in combination with
a targeted antiangiogenic drug, such as an anti–VEGFR-2 antibody
[21]. Such low-dose metronomic chemotherapy dosing and administra-
tion schedules are thought to inhibit tumor growth primarily by anti-
angiogenic mechanisms including the direct targeting of endothelial
cells in the tumor neovasculature and circulating bone marrow–derived
endothelial progenitor cells [5,21,22,30,43], although additional mecha-
nisms are possible as well. Thus, the presence or absence of liver cirrhosis
may not significantly impact the relative therapeutic outcomes of HCC
therapy experiments using metronomic chemotherapy and/or targeted
antiangiogenic drugs. Indeed, a recent study [44] showed that a metro-
nomicCTX regimen could be used to safely and successfully treat a spon-
taneous rat hepatoma induced by chemical carcinogenesis where tumors
were accompanied by liver cirrhosis [44]. By comparison, a maximum
tolerated dose control arm was much more toxic and not as effective
as the metronomic regimen [44]. In this regard, clinical trials testing
metronomic UFT chemotherapy in combination with sorafenib have
been initiated in advanced HCC patients (http://www.clinicaltrials.
gov). Conversely, because UFTand CTX are both prodrugs that are ac-
tivated by liver enzymes, it is possible that encouraging preclinical re-
sults may not be obtained in the clinic, at least in some cases, as a
result of the presence of liver cirrhosis. In this regard, the aforementioned
results by Park et al. [44] are reassuring with respect to the use of metro-
nomic chemotherapy using a prodrug where liver cirrhosis is present.
Nevertheless, additional studies using the metronomic chemotherapy
protocols we have used in mice with liver cirrhosis will be required to
determine whether the treatments are not overtly toxic and also main-
tain their efficacy.
In our studies, we tested several metronomic chemotherapy regi-
mens: metronomic UFT alone, metronomic CTX alone, or both to-
gether; metronomic DOX alone, or with UFT, or CTX. We also tested
DC101 alone or with the aforementioned metronomic chemotherapy
regimens. The major finding is that no single or doublet metronomic
chemotherapy regimen tested, or DC101 alone, had any demonstrable
benefit in prolonging survival, when treatment was initiated on advanced
orthotopic human HCC. In contrast, almost all combinations of con-
current combination metronomic chemotherapy regimens plus DC101
meaningfully prolonged survival and did so with minimal overt toxicity.
As such, our results highlight the possibility that even if metronomic
chemotherapy per se fails to cause a clinical benefit, combination with
a targeted antiangiogenic drug could yield results superior to the anti-
angiogenic drug used alone. This possibility should now be considered
for the use of drugs such as UFTwhen used in the adjuvant treatment
setting. Indeed, UFT has shown a clinical benefit when administered
postsurgically for the adjuvant treatment of a number of early stage can-
cers such as non–small cell lung carcinoma [25], breast cancer [45], and
gastric cancer [46], but not necessarily HCC [47,48], although this is
controversial [49]. However, a combination of antiangiogenic drugs with
metronomic UFTmay provide a clinical benefit exceeding either ther-
apy used alone. In any case, the results of the therapy studies using our
newly developed HCC model suggest that metronomic CTX plus UFT
combined with a VEGF pathway–targeting antibody drug may be a
potentially interesting and promising new therapeutic strategy for the
treatment of this disease. It will be of interest to test metronomic UFT
monochemotherapy with an antiangiogenic drug to determine whether
it has an activity comparable to UFT + CTX or UFT + DOX.
With respect to antiangiogenic drugs, the proven benefit of small
molecule with oral antiangiogenic RTKIs such as sorafenib in treating
advanced human HCC would make them obvious promising can-
didates for combination with metronomic chemotherapy. This would
provide an oral combination therapy when using drugs such as UFT
and CTX for the metronomic chemotherapy. In addition, because the
toxicities associated with drugs such as sorafenib sometimes require
frequent interruptions in the otherwise daily therapy schedule [50–
52], treatment with the minimally toxic metronomic chemotherapy
regimens could be continued during such interruptions, thereby mini-
mizing the possible drawbacks associated with interrupting RTKI anti-
angiogenic therapy such as rapid “rebound” of tumor growth [53,54].
Table 1. Median Survival and Statistical Significance of Metronomic Chemotherapy Treatments
without or with DC101.
Test Groups Median Survival (Days) P
Figure 5A
Control 42 –
CTX 49 .5454
UFT 50 .3896
DOX 42 .8913
CTX + UFT 49 .4855
DOX + UFT 50 .4875
Figure 5B
Control 48.5 –
DC101 48.5 .9089
CTX + UFT 49 .8118
DOX + UFT 42 .8738
CTX + UFT + DC101 78.5 .0067
DOX + UFT + DC101 73.5 .0266
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